Topic
Welcome
Pharma Strategy: Sustainable growth, more patient benefits, and less cost to society
Commercial Opportunities
Late Stage Pipeline Oncology & Non-malignant Hematology
Late Stage Pipeline Neuroscience
Late Stage Pipeline Immunology & Ophthalmology
Infectious Disease: A close look at the HBV pipeline
Late Stage Infectious Diseases: Influenza & SARS-CoV-2
Presenter
Karl Mahler, Head of Investor Relations and Roche Group Planning
Bill Anderson, Chief Executive Officer Roche Pharmaceuticals
Teresa Graham, Head of Pharma Global Product Strategy
Levi Garraway, Chief Medical Officer and Head Global Product Development
Paulo Fontoura, Global Head Neuroscience and Rare Diseases Clinical Development
Cristin Hubbard, Head I2O (Immunology, Infectious Diseases, Ophthalmology) Global Product Strategy
John Young, Global Head of Infectious Diseases, Roche Pharma Research & Early Development
Cristin Hubbard, Head I2O (Immunology, Infectious Diseases, Ophthalmology) Global Product Strategy